Aprepitant USP
Composition : Each Capsule Contains Aprepitant USP40mg.
Indications : Apridex
is indicated for- Prevention of postoperative nausea and vomiting (PONV).
Prevention of chemotherapy induced nausea and vomiting (CINV).
Dosage and administration
Post Operative Nausea and Vomiting:
The recommended oral dosage of Aprepitant is 40 mg within 3 hours prior to
induction of anesthesia.
Chemotherapy-Induced Nausea and Vomiting:
The following regimen should be used for the prevention of nausea and vomiting
associated with highlyemetogenic cancer chemotherapy-
Day 1: Aprepitant 125
mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): 24 mg
30minutes before the start of chemotherapy.
Day 2: Aprepitant 80
mg orally, Dexamethasone 8 mg orally
Day 3: Aprepitant 80
mg orally, Dexamethasone 8 mg orally
Day 4: Dexamethasone
8 mg orally
Aprepitant is administered orally 1 hour prior to
chemotherapy treatment on Day 1 and in the morning on Days 2 and3.
Dexamethasone is administered 30 minutes prior to chemotherapy treatment on Day
1 and in the morning on Days2 through 4. The dose of dexamethasone accounts for
drug interactions.** The following regimen should be used for the prevention of
nausea and vomiting associated with moderately emetogenic cancer chemotherapy:
Day 1: Aprepitant 125
mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): one 8 mg
tablet30 minutes before chemotherapy followed by an 8 mg dose 8 hours later.
Day 2: Aprepitant 80
mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day
Day 3: Aprepitant 80
mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day.
Apridex is administered orally 1
hour prior to chemotherapy treatment on Day 1 and in the morning on Days 2 and
3.
Dexamethasone is administered 30
minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone
accounts for drug interactions.
Apridex may be taken with or without food. No dosage adjustment is necessary
for
the elderly patients. Patients
with Renal Impairment- No dosage adjustment isnecessary for patients with renal
impairment or for patients with end stage renal disease (ESRD) undergoing
hemodialysis. Patients with Hepatic Impairment-No dosage adjustment is
necessary for patients with mild to moderate hepatic impairment. There are no
clinical data in patients with severe hepatic impairment. Or, as directed by
the registered physician.
Use in pregnancy and lactation :Pregnancy: Pregnancy Category B. There are no adequate and well controlled
studies in pregnant
women. Aprepitant should be used during pregnancy only if clearly needed. It is
not known
whether this drug is excreted in human
milk.
Packing :Each box contains 1 x 5’s capsules in blisterpack.
